For research use only. Not for therapeutic Use.
Ropidoxuridine (IPdR) is a novel orally available, halogenated thymidine analog and is a potential radiosensitizer for use in human tumors.
Ropidoxuridine is an orally bioavailable pro-drug of IUdR (5-iodo-2′-deoxyuridine). Ropidoxuridine demonstrates strong synergy effects with Alisertib at clinically relevant concentrations[1].
In an orthotopic tumor model, Ropidoxuridine (750 mg/kg/day) and Alisertib (30 mg/kg/day) demonstrate strong synergy effects[1].
| Catalog Number | I009183 |
| CAS Number | 93265-81-7 |
| Synonyms | 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one |
| Molecular Formula | C9H11IN2O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C9H11IN2O4/c10-5-2-11-9(15)12(3-5)8-1-6(14)7(4-13)16-8/h2-3,6-8,13-14H,1,4H2/t6-,7+,8+/m0/s1 |
| InChIKey | XIJXHOVKJAXCGJ-XLPZGREQSA-N |
| SMILES | C1C(C(OC1N2C=C(C=NC2=O)I)CO)O |
| Reference | [1]. Rampurwala MM, et al. Ropidoxuridine (IPdR) potentiates alisertib (MLN8237) activity in triple-negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-13-16. |
